Tenderwize
Retour à la recherche

Open-house framework agreement for Aripiprazole depot injection suspension

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jul 03, 2027 · 308 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Aripiprazol in der Darreichungsform Depot-Injektionssuspension, ATC N05AX12 (Kopie)

56/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

56 / 100

Complexité

48 / 100

Facteurs de risque

Contract documents must be submitted through the DTVP communication area, not the offer area; wrong channel could jeopa...

The last possible date for contract conclusion is 2027-07-03, and monthly start dates depend on the 3rd of the month cu...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Non-exclusive pharmaceutical rebate agreements for Aripiprazole depot injection suspension (ATC N05AX12).
  • Framework/open-house arrangement under § 130a(8) SGB V, with identical, non-individually negotiable contract terms.
Afficher le résumé complet

Open-house supply arrangement for Aripiprazole depot injection suspension (ATC N05AX12) in Germany, led by AOK Bayern. The model is non-exclusive and open to all pharmaceutical companies that meet the stated self-declared reliability requirement. No contract value is provided. Submission is via DTVP or by signed paper originals; the deadline for contracts starting on the next month begins on the 3rd of the previous month, and the final contract conclusion date is 2027-07-03.

Risques

Contract documents must be submitted through the DTVP communication area, not the offer area; wrong channel could jeopa...

The last possible date for contract conclusion is 2027-07-03, and monthly start dates depend on the 3rd of the month cu...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • The signatory's authority must be evidenced by the commercial register excerpt; otherwise a power of attorney is required.

Eligibility

  • Only pharmaceutical companies are eligible as potential contractual partners.

Administrative

  • Submit the completed and signed contract, completed and signed Annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and completed and signed self-declaration on...

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open-house framework agreement for Aripiprazole depot injection suspension

Lot 1 covers non-exclusive open-house rebate agreements for Aripiprazole in depot injection suspension form (ATC N05AX12). The notice states this is an open-house model, not a competitive open procedure, and contracts are offered on identical, non-negotiable terms to qualifying pharmaceutical companies. The lot is sourced from structured data and XML notice.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Aug 2025 - Aug 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Jul 03, 2027

Détails de la procédure

Date de publication
24 Jul 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
488809-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30